Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2022-05-16 00:00:00 ET · period of report 2022-05-12 · accession 0001562180-22-004031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-16 | 2022-05-12 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | A - Grant | $0.00 | +200.0K | 417.7K | +92% | $0 |
| D | 2022-05-16 | 2022-05-12 | AKBA | Burke Steven Keith | SVP, Chief Medical Off | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-12 | A | A | 200,000 | $0.00 | 417,663 | D | — | — | (F1) The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The restricted stock units will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. |
| 2 | Derivative | Stock Option (Right to buy) | 2022-05-12 | A | A | 200,000 | $0.00 | 200,000 | D | $0.41 · 2023-05-12 to 2032-05-12 | 200,000 Common Stock | (F2) The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest in full on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer on such vesting date. |